Cobra Score Adequately Identifies Higher Risk Of Cancer Mortality And Lymphovascular Invasion Information Further Improves Its Performance

You have accessJournal of UrologyBladder Cancer: Invasive I (MP13)1 Sep 2021MP13-11 COBRA SCORE ADEQUATELY IDENTIFIES HIGHER RISK OF CANCER MORTALITY AND LYMPHOVASCULAR INVASION INFORMATION FURTHER IMPROVES ITS PERFORMANCE Anna Colomer Gallardo, Oscar Buisan Rueda, Roger Freixa Sala, Petr Macek, Yann Barbe, Xavier Cathelineau, Marco Moschini, Rafael Sánchez-Salas, and Joan Areal Calama Anna Colomer GallardoAnna Colomer Gallardo More articles by this author , Oscar Buisan RuedaOscar Buisan Rueda More articles by this author , Roger Freixa SalaRoger Freixa Sala More articles by this author , Petr MacekPetr Macek More articles by this author , Yann BarbeYann Barbe More articles by this author , Xavier CathelineauXavier Cathelineau More articles by this author , Marco MoschiniMarco Moschini More articles by this author , Rafael Sánchez-SalasRafael Sánchez-Salas More articles by this author , and Joan Areal CalamaJoan Areal Calama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001994.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To externally validate the COBRA score (tool predicting cancer-specific survival after radical cystectomy for urothelial carcinoma; Welty et al Cancer 2017, DOI: 10.1002/cncr.30918) and to add lymphovascular invasion(LVI) information from cystectomy final pathology to verify its impact on the predictive model. METHODS: Clinicopathological and survival data from 789 patients who underwent radical cystectomy and pelvic lymph node dissection between January 2007 and December 2020 were analysed. External validation was determined using regression coefficients abstracted from previously published data. COBRA score was applied to our sample and Cancer Specific Survival (CSS) Kaplan-Meier (KM) curves were performed. After adding LVI new CCS curves were plotted. RESULTS: A total 789 patients were analyzed, with median follow up of 32 months. Cancer Specific Mortality was 218 patients (27,6%). When COBRA score was applied to our cohort, the discriminatory power was found to have high precision with a c- index of 71% for the full model.Regression COX analysis showed Group 1 HR 0.36, IC (0.16-0.83), p=0.016; Group 2 HR 0, IC (0-1.77) p=0.94; Group 3 HR 0.51, IC (0.39 -0.67), p=0.001; Group 4 HR 1.67, IC (1.23-2.27), p=0.001; Group 5 HR 2.45, IC (1.51-3.99); p=0.001; Group 6 HR 2.01, IC (1.42-2.85), p=0.001; Group 7 HR 0.66, IC (0.09-4.73), p=0.682. KM curves for COBRA score in our sample are presented. When the LVI was added to the model, a poorer CSS was verified (Figure 1, without LVI vs with LVI). CONCLUSIONS: COBRA adequately identifies those patients with a higher risk of cancer mortality in our population. Furthermore, adding LVI information further improves the prediction. LVI could be further evaluated and eventually included in the prediction model. Source of Funding: No source of funding © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e247-e247 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Anna Colomer Gallardo More articles by this author Oscar Buisan Rueda More articles by this author Roger Freixa Sala More articles by this author Petr Macek More articles by this author Yann Barbe More articles by this author Xavier Cathelineau More articles by this author Marco Moschini More articles by this author Rafael Sánchez-Salas More articles by this author Joan Areal Calama More articles by this author Expand All Advertisement Loading ...